Dow Falls More Than 400 Points; Pfizer Reports Earnings Exceeding Expectations
Market Performance: U.S. stocks opened lower, with the Dow Jones dropping over 400 points, while the NASDAQ and S&P 500 also experienced declines of 1.59% and 1.17%, respectively.
Sector Movements: Consumer staples saw a slight increase of 0.5%, while information technology stocks fell by 1.8%.
Pfizer Earnings Report: Pfizer reported better-than-expected third-quarter earnings, with adjusted earnings of 87 cents, surpassing the consensus estimate, despite a 6% decline in sales year-over-year.
Equities Activity: Evoke Pharma's shares surged 135% following an acquisition announcement, while Prelude Therapeutics saw a 56% drop after signing an acquisition agreement that negatively impacted its stock.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on PTLE
About PTLE
About the author
Gold Drops More Than 1%; Uber Stock Decreases Following Q3 Earnings Report
Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow fell 0.60% and the S&P 500 decreased by 1.05%.
Sector Movements: Financial shares rose by 0.4%, but information technology stocks fell by 1.8%, reflecting mixed sector performance.
Notable Stock Movements: Uber's stock fell over 6% despite reporting strong revenue growth, while Evoke Pharma surged 133% after announcing an acquisition.
Global Market Trends: European and Asian markets mostly closed lower, with Japan's Nikkei 225 down 1.74% and the eurozone's STOXX 600 declining 0.30%.
Dow Falls More Than 400 Points; Pfizer Reports Earnings Exceeding Expectations
Market Performance: U.S. stocks opened lower, with the Dow Jones dropping over 400 points, while the NASDAQ and S&P 500 also experienced declines of 1.59% and 1.17%, respectively.
Sector Movements: Consumer staples saw a slight increase of 0.5%, while information technology stocks fell by 1.8%.
Pfizer Earnings Report: Pfizer reported better-than-expected third-quarter earnings, with adjusted earnings of 87 cents, surpassing the consensus estimate, despite a 6% decline in sales year-over-year.
Equities Activity: Evoke Pharma's shares surged 135% following an acquisition announcement, while Prelude Therapeutics saw a 56% drop after signing an acquisition agreement that negatively impacted its stock.
